Nuvation Bio Inc. (NYSE:NUVB) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of Nuvation Bio Inc. (NYSE:NUVB) have been given an average rating of “Moderate Buy” by the eight analysts that are covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, six have assigned a buy rating and one has given a strong buy rating to the company. The average 12-month price target among brokers that have covered the stock in the last year is $7.8571.

NUVB has been the subject of a number of research reports. Jefferies Financial Group initiated coverage on shares of Nuvation Bio in a report on Tuesday, September 30th. They issued a “buy” rating and a $10.00 target price for the company. Royal Bank Of Canada increased their price objective on shares of Nuvation Bio from $6.00 to $7.00 and gave the company an “outperform” rating in a research note on Friday, August 8th. Weiss Ratings reissued a “sell (d-)” rating on shares of Nuvation Bio in a research note on Wednesday, October 8th. JMP Securities reiterated a “market outperform” rating and issued a $6.00 price target on shares of Nuvation Bio in a research note on Wednesday, June 25th. Finally, Wedbush reiterated an “outperform” rating and issued a $6.00 price target on shares of Nuvation Bio in a research note on Monday.

Nuvation Bio Stock Down 3.4%

NYSE NUVB opened at $3.56 on Wednesday. The business has a fifty day moving average price of $3.14 and a two-hundred day moving average price of $2.48. The company has a debt-to-equity ratio of 0.13, a current ratio of 9.39 and a quick ratio of 9.38. Nuvation Bio has a fifty-two week low of $1.54 and a fifty-two week high of $4.09. The stock has a market capitalization of $1.22 billion, a PE ratio of -5.64 and a beta of 1.48.

Nuvation Bio (NYSE:NUVB) last announced its quarterly earnings data on Thursday, August 7th. The company reported ($0.17) earnings per share for the quarter, hitting the consensus estimate of ($0.17). Nuvation Bio had a negative return on equity of 46.14% and a negative net margin of 1,413.43%.The business had revenue of $4.83 million during the quarter, compared to the consensus estimate of $0.42 million. Equities analysts expect that Nuvation Bio will post -0.36 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Wealth Enhancement Advisory Services LLC bought a new position in Nuvation Bio in the 4th quarter valued at approximately $27,000. Highline Wealth Partners LLC bought a new position in shares of Nuvation Bio during the second quarter valued at $25,000. Rangeley Capital LLC bought a new position in shares of Nuvation Bio during the second quarter valued at $25,000. Cetera Investment Advisers bought a new position in Nuvation Bio during the 2nd quarter worth $29,000. Finally, Captrust Financial Advisors bought a new position in Nuvation Bio during the 2nd quarter worth $32,000. Institutional investors own 61.67% of the company’s stock.

Nuvation Bio Company Profile

Nuvation Bio Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer.